ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.

about

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.

Item

http://www.wikidata.org/entity/Q49516382

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

ASXL1 frameshift mutations dri ...... ithout negative impact in MDS.

@en

ASXL1 frameshift mutations dri ...... ithout negative impact in MDS.

@nl

type

Item

label

ASXL1 frameshift mutations dri ...... ithout negative impact in MDS.

@en

ASXL1 frameshift mutations dri ...... ithout negative impact in MDS.

@nl

prefLabel

ASXL1 frameshift mutations dri ...... ithout negative impact in MDS.

@en

ASXL1 frameshift mutations dri ...... ithout negative impact in MDS.

@nl

P1476

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS

@en

P2093

Christine Vaupel

http://www.w3.org/2001/XMLSchema#string

David A Sallman

http://www.w3.org/2001/XMLSchema#string

Eric Padron

http://www.w3.org/2001/XMLSchema#string

Jeff Hall

http://www.w3.org/2001/XMLSchema#string

Jeffrey Lancet

http://www.w3.org/2001/XMLSchema#string

Jinming Song

http://www.w3.org/2001/XMLSchema#string

Najla H Al Ali

http://www.w3.org/2001/XMLSchema#string

Rami Komrokji

http://www.w3.org/2001/XMLSchema#string

Thomas Cluzeau

http://www.w3.org/2001/XMLSchema#string

P2860

ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression

Clinical effect of point mutations in myelodysplastic syndromes

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome.

P2888

s41408-017-0004-0

P304

633

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41408-017-0004-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alan F List

P577

2017-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092959398

http://www.w3.org/2001/XMLSchema#string

P698

29176559

http://www.w3.org/2001/XMLSchema#string

P932

5802523

http://www.w3.org/2001/XMLSchema#string